Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James(Royal Marsden NHS Foundation Trust), Mahesh Parmar(University College London)

The Lancet

December 21, 2015

10.1016/s0140-6736(15)01037-5

Cited by 1,957

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

|New England Journal of Medicine|2013|3.3k

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

|The Lancet Oncology|2014|491

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

|The Lancet Oncology|2014|194

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

|European Urology|2019|191